Sirolimus versus paclitaxel coronary stents in clinical practice
✍ Scribed by Niklas Millauer; Peter Jüni; Alexandra Hofmann; Simon Wandel; Anupham Bhambhani; Michael Billinger; Niklaus Urwyler; Peter Wenaweser; Gerrit Hellige; Lorenz Räber; Stéphane Cook; Rolf Vogel; Mario Togni; Christian Seiler; Bernhard Meier; Stephan Windecker
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 230 KB
- Volume
- 77
- Category
- Article
- ISSN
- 1522-1946
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objectives: The purpose of this study was to examine the clinical outcomes of patients who underwent stenting with ≥3 sirolimus‐eluting stents (SES) when compared with those treated with ≥3 paclitaxel‐eluting stents (PES). ## Background: Drug‐eluting stent (DES) implantation for s
## Abstract Objectives and Background: First generation drug‐eluting stents have shown differential efficacy in high‐risk patient subsets at one year. It is unclear whether these differences endure over the medium‐ to long‐term. We compared the five‐year clinical efficacy and safety of sirolimus‐el
## Abstract Objective: This study compared the efficacy of the sirolimus‐eluting stent (SES), the paclitaxel‐eluting stent (PES), and the bare metal stent (BMS) for long coronary lesions. Background: The outcome of drug‐eluting stent (DES) implantation in long coronary lesions remains unclear. Meth